Author

Kensuke Ofuchi

Observed name: Ofuchi, Kensuke

Observed institution: Ibaraki Nature Museum

OpenAlex ID: A5021102518

Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study

2023 · Takeshi Osonoi, Miyoko Saito, et al. · Frontiers in Endocrinology · 14

Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia

2023 · Takeshi Osonoi, Shinichiro Shirabe, et al. · Diabetes Metabolic Syndrome and Obesity · 12

Liraglutide Improves Estimated Glomerular Filtration Rate Slopes in Patients with Chronic Kidney Disease and Type 2 Diabetes: A 7-Year Retrospective Analysis

2020 · Takeshi Osonoi, Miyoko Saito, et al. · Diabetes Technology & Therapeutics · 12

Effects of barley intake on glycemic control in Japanese patients with type 2 diabetes mellitus undergoing antidiabetic therapy: a prospective study

2021 · Takeshi Osonoi, Tsubasa Matsuoka, et al. · Diabetology International · 8

Canagliflozin Increases Postprandial Total Glucagon-Like Peptide 1 Levels in the Absence of α-Glucosidase Inhibitor Therapy in Patients with Type 2 Diabetes: A Single-Arm, Non-randomized, Open-Label Study

2019 · Takeshi Osonoi, Atsuko Tamasawa, et al. · Diabetes Therapy · 6

Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial

2023 · Takeshi Osonoi, Shinichiro Shirabe, et al. · Frontiers in Pharmacology · 4

Imeglimin may affect hemoglobin A1c accuracy via prolongation of erythrocyte lifespan in patients with type 2 diabetes mellitus: insights from the INFINITY clinical trial

2025 · Takeshi Osonoi, Shinichiro Shirabe, et al. · Frontiers in Endocrinology · 3

Switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, may substantially reduce serum urate levels, through URAT1 inhibition, potentially without adversely affecting ABCG2 function: findings from the SWITCH SURI study

2025 · Takeshi Osonoi, Shinichiro Shirabe, et al. · Frontiers in Endocrinology · 3

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study

2020 · Takeshi Osonoi, Miyoko Saito, et al. · Diabetes Metabolic Syndrome and Obesity · 2

Imeglimin Treatment May Improve Whole-Blood Fluidity and Influence Hemorheology in Patients with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the INFINITY Study

2026 · Takeshi Osonoi, Shinichiro Shirabe, et al. · Journal of Personalized Medicine · 1

Imeglimin-Associated Temporal Changes in γ-Glutamyl Transferase and Total Cholesterol: A Post Hoc Exploratory Analysis of the INFINITY Study

2026 · Takeshi Osonoi, Shinichiro Shirabe, et al. · Journal of Personalized Medicine

SGLT2 Inhibitors Improve a Decline in Renal Function in Type 2 Diabetic Patients with Chronic Renal Dysfunction: A Retrospective Observational Study

2020 · Takeshi Osonoi, Miyoko Saito, et al. · 診療と新薬

Annual Changes in the Profile of Type 2 Diabetic Patients with Glinide Therapy from 2008 to 2019 and Effects of Mitiglinide and Voglibose Combination Tablets (Glubes Combination Tablets) in Patients with Type 2 Diabetes Mellitus

2020 · Takeshi Osonoi, Miyoko Saito, et al. · 診療と新薬

Long-term Clinical Efficacy of an Oral Adsorbent AST-120 (KREMEZIN) in Patients with Severe and End Stages of Chronic Kidney Disease and Type 2 Diabetes

2020 · Takeshi Osonoi, Miyoko Saito, et al. · 診療と新薬

Works count: 15

Citation count: 65

H-index: 5

I10-index: 3